ImmunityBio (IBRX) director Christobel Selecky awarded 65,600 stock options at $7.25

Rhea-AI Filing Summary

ImmunityBio, Inc. director Christobel Selecky received a grant of stock options covering 65,600 shares of common stock. The options have an exercise price of $7.25 per share and expire on June 9, 2036.

Subject to Selecky continuing as a “Service Provider” under the company’s 2025 Equity Incentive Plan, 100% of the options will vest on the earlier of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders. Following this grant, Selecky holds 65,600 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Selecky Christobel

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	65,600	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 65,600 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 65,600 options Exercise price: $7.25 per share Underlying shares: 65,600 shares +3 more

6 metrics

Options granted 65,600 options Stock Option (right to buy) grant to director

Exercise price $7.25 per share Conversion or exercise price of stock options

Underlying shares 65,600 shares Common Stock underlying the options

Expiration date June 9, 2036 Option term end date

Post-grant option holdings 65,600 options Total options held following transaction

Vesting trigger date June 9, 2027 Earlier of this date or immediately before next annual meeting

Key Terms

Stock Option (right to buy), 2025 Equity Incentive Plan, Service Provider, vesting

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

2025 Equity Incentive Plan financial

"defined in the Issuer's 2025 Equity Incentive Plan"

Service Provider financial

"continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan)"

vesting financial

"100% of the shares subject to the award will vest on the earlier"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Selecky Christobel

(Last) (First) (Middle)

C/O IMMUNITYBIO, INC.

3530 JOHN HOPKINS COURT

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ImmunityBio, Inc. [ IBRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.25	06/09/2026		A		65,600		(1)	06/09/2036	Common Stock	65,600	$0	65,600	D

Explanation of Responses:

1. Subject to the reporting person's continuing to be a Service Provider (as defined in the Issuer's 2025 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of June 9, 2027 or the date immediately preceding the next annual meeting of stockholders.

Remarks:

	/a/ David C. Sachs, as Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ImmunityBio (IBRX) director Christobel Selecky report on this Form 4?

Christobel Selecky reported receiving a grant of stock options for 65,600 shares of ImmunityBio common stock. These options are a compensation award, not an open-market purchase, and were granted at an exercise price of $7.25 per share with long-term expiration.

What are the key terms of Christobel Selecky’s ImmunityBio (IBRX) stock options?

The grant covers 65,600 underlying shares at an exercise price of $7.25 per share and expires on June 9, 2036. All options vest at once on a future date, subject to continued service with the company as defined in its 2025 Equity Incentive Plan.

When will Christobel Selecky’s ImmunityBio (IBRX) stock options vest?

All 65,600 options will vest 100% on the earlier of June 9, 2027, or the date immediately preceding ImmunityBio’s next annual meeting of stockholders. Vesting depends on Selecky’s continued status as a Service Provider under the company’s 2025 Equity Incentive Plan.

Is Christobel Selecky buying or selling ImmunityBio (IBRX) shares in this filing?

The filing shows an option grant, not a market trade. Selecky acquired stock options as a compensation award, coded as a grant/award acquisition, and did not report any open-market buying or selling of ImmunityBio common shares in this Form 4.

How many ImmunityBio (IBRX) stock options does Christobel Selecky hold after this grant?

After this grant, Selecky holds 65,600 stock options directly, all tied to ImmunityBio common stock. These options were entirely acquired in this single transaction and remain subject to future vesting and potential exercise at the stated $7.25 strike price.